NCT02715505View on ClinicalTrials.gov

Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 10, 2017

Primary Completion Date

May 18, 2020

Study Completion Date

May 18, 2020

Conditions
Inherited Metabolic Disorders IMD
Interventions
DRUG

Umbilical cord blood transplantation with HSC835

Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY